Bruker Corporation (NASDAQ:BRKR) Receives Average Recommendation of "Hold" from Analysts

Key Points

• Bruker Corporation has received a consensus rating of "Hold" from analysts, with six firms recommending hold and five recommending buy.
• The company recently missed its earnings estimate, reporting $0.32 earnings per share, compared to the expected $0.33.
• Bruker has announced a quarterly dividend of $0.05 per share, representing an annualized yield of 0.6%.

Bruker Corporation (NASDAQ:BRKR - Get Free Report) has been assigned a consensus rating of "Hold" from the eleven research firms that are presently covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $51.30.

BRKR has been the topic of several recent research reports. Wells Fargo & Company cut their target price on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 5th. Jefferies Financial Group set a $60.00 target price on shares of Bruker and gave the stock a "buy" rating in a research note on Monday, August 4th. Barclays dropped their price objective on shares of Bruker from $46.00 to $43.00 and set an "overweight" rating on the stock in a research report on Monday, August 4th. Stifel Nicolaus set a $40.00 price objective on shares of Bruker and gave the company a "hold" rating in a research report on Tuesday, August 5th. Finally, Citigroup dropped their price objective on shares of Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a research report on Monday, August 4th.

Bruker Price Performance

Shares of BRKR opened at $31.04 on Monday. Bruker has a fifty-two week low of $28.53 and a fifty-two week high of $72.94. The firm's 50 day moving average price is $34.04 and its 200 day moving average price is $37.83. The company has a market cap of $4.71 billion, a P/E ratio of 59.69, a PEG ratio of 4.32 and a beta of 1.22. The company has a quick ratio of 0.70, a current ratio of 1.61 and a debt-to-equity ratio of 1.31.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a return on equity of 17.89% and a net margin of 2.31%.The business had revenue of $797.40 million for the quarter, compared to analysts' expectations of $811.17 million. During the same period in the previous year, the company earned $0.52 earnings per share. Bruker's quarterly revenue was down .4% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, research analysts forecast that Bruker will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd will be given a $0.05 dividend. The ex-dividend date of this dividend is Tuesday, September 23rd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. Bruker's dividend payout ratio is currently 38.46%.

Insider Activity at Bruker

In other Bruker news, Director Cynthia M. Friend sold 3,535 shares of the stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the sale, the director directly owned 18,016 shares of the company's stock, valued at approximately $581,016. This represents a 16.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 27.30% of the company's stock.

Institutional Investors Weigh In On Bruker

A number of large investors have recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC grew its position in shares of Bruker by 25.5% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 16,459 shares of the medical research company's stock valued at $965,000 after buying an additional 3,349 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its position in shares of Bruker by 274.9% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock valued at $46,000 after buying an additional 800 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Bruker by 4,299.2% in the 1st quarter. GAMMA Investing LLC now owns 56,266 shares of the medical research company's stock valued at $2,349,000 after buying an additional 54,987 shares during the last quarter. Rhumbline Advisers grew its position in shares of Bruker by 1.2% in the 1st quarter. Rhumbline Advisers now owns 317,267 shares of the medical research company's stock valued at $13,243,000 after buying an additional 3,763 shares during the last quarter. Finally, Merit Financial Group LLC grew its position in shares of Bruker by 226.9% in the 1st quarter. Merit Financial Group LLC now owns 16,722 shares of the medical research company's stock valued at $698,000 after buying an additional 11,607 shares during the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.